Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Iloprost. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 2/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 2/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 2/20 | 1.00 |
| ▸ | PTGER1 | P34995 | 1/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 1/20 | 1.00 |
| ▸ | PPARD | Q03181 | 2/20 | 0.64 |
| ▸ | PPARA | Q07869 | 2/20 | 0.64 |
| ▸ | PPARG | P37231 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 12/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iloprost SCHEMBL17510362 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Iloprost SCHEMBL532498 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Iloprost SCHEMBL13658124 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Iloprost SCHEMBL21509111 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Iloprost SCHEMBL21509108 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Iloprost SCHEMBL21509107 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Iloprost SCHEMBL21509137 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Iloprost SCHEMBL21509174 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Iloprost SCHEMBL20687610 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Iloprost SCHEMBL532499 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| CN-119725997-A | Separator, preparation method thereof and lithium ion battery | 上海轩邑新能源发展有限公司 | 2025-03-28 | — | — | CN | claimed |
| US-20220381405-A1 | Theragnostic Endoprosthetic Spacer | KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITÄT MÜNCHEN (DE) | 2022-12-01 | — | — | US | claimed |
| EP-4031067-A1 | ENDOPROSTHESIS AND METHOD OF MANUFACTURING AN ENDOPROSTHESIS | Kardiozis SAS (FR) | 2022-07-27 | — | — | EP | claimed |
| US-11278627-B2 | Antibody-drug conjugates and the use of same in therapy | MC SAF (FR) | 2022-03-22 | — | — | US | claimed |
| EP-1089970-B1 | OXIDATION INHIBITORS FOR PROSTANE DERIVATIVES | SCHERING AG (DE) | 2004-04-07 | — | — | EP | claimed |
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | PHARMOSA BIOPHARM INC. (TW) | 2026-05-28 | — | — | US | disclosed |
| EP-4746889-A1 | METHOD OF USING ILOPROST FOR TREATING FROSTBITE | BTG International Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-12616695-B2 | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases | METRIOPHARM AG (CH) | 2026-05-05 | — | — | US | disclosed |
| EP-3969002-B1 | PHARMACEUTICAL COMPOSITION OF A WEAK ACID DRUG AND METHODS OF ADMINISTRATION | PHARMOSA BIOPHARM INC (TW) | 2026-04-22 | — | — | EP | disclosed |
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | disclosed |
| US-20260069535-A1 | NEBULIZER KITS AND USES THEREOF | PHARMOSA BIOPHARM INC (TW) | 2026-03-12 | — | — | US | disclosed |
| US-20150025255-A1 | PROCESS FOR PREPARING SYNTHETIC PROSTACYCLINS | LUNG BIOTECHNOLOGY INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20120315303-A1 | METHODS AND INTRAVASCULAR TREATMENT DEVICES USING PACLITAXEL FOR TREATMENT OF ATHEROSCLEROSIS | MEDTRONIC VASCULAR, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120270934-A1 | PROSTACYCLIN DERIVATIVES | CONCERT PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | disclosed |
| WO-2011003058-A1 | PROSTACYCLIN DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-7071359-B1 | Neuropathy improvers containing nitrogenous compounds as the active ingredient | TEIJIN LIMITED (JP) | 2006-07-04 | — | — | US | disclosed |
| EP-1201235-B1 | NEUROPATHY IMPROVERS CONTAINING NITROGENOUS COMPOUNDS AS THE ACTIVE INGREDIENT | TEIJIN LTD (JP) | 2005-10-12 | — | — | EP | disclosed |
| EP-1201235-A1 | NEUROPATHY IMPROVERS CONTAINING NITROGENOUS COMPOUNDS AS THE ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 2002-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | PTGIR 1717/4885PTGER3 2667/4885PTGER2 1921/4885 |
| US-20150025255-A1 | PROCESS FOR PREPARING SYNTHETIC PROSTACYCLINS | PTGIS, PTGIR, PTGES | PTGIR 2/4885PTGER3 21/4885PTGER2 11/4885 |
| US-20260069535-A1 | NEBULIZER KITS AND USES THEREOF | PTGER2, PTGER1, PTGIR | PTGIR 3/4885PTGER3 10/4885PTGER2 1/4885 |
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | LIPA, NSF, SLC26A3 | PTGIR 730/4885PTGER3 1705/4885PTGER2 1050/4885 |
| US-20120315303-A1 | METHODS AND INTRAVASCULAR TREATMENT DEVICES USING PACLITAXEL FOR TREATMENT OF ATHEROSCLEROSIS | PCSK9, PLAT, PCSK7 | PTGIR 110/4885PTGER3 946/4885PTGER2 1576/4885 |
| US-12616695-B2 | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases | CRYZ, PDE12, FKBP5 | PTGIR 3765/4885PTGER3 2347/4885PTGER2 2721/4885 |
| US-20120270934-A1 | PROSTACYCLIN DERIVATIVES | PTGIS, PTGIR, PTGER1 | PTGIR 2/4885PTGER3 7/4885PTGER2 8/4885 |
| US-11278627-B2 | Antibody-drug conjugates and the use of same in therapy | CD47, TNFRSF9, VSIG8 | PTGIR 4424/4885PTGER3 4637/4885PTGER2 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.